Key takeaways
Wegovy ingredients include the active ingredient semaglutide, a GLP-1 that causes weight loss by reducing appetite and lowering blood sugar.
Inactive ingredients in Wegovy tablets include magnesium stearate and salcaprozate sodium (SNAC). Inactive ingredients in Wegovy injections are water, salt, and other non-active ingredients that help stabilize or adjust pH. Wegovy injections are preservative-free.
Though not common, an allergic reaction to any of Wegovy’s ingredients (active or inactive) is possible. Seek medical attention for symptoms like trouble breathing, facial swelling, hives, or fainting.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Wegovy ingredients include the active ingredient semaglutide, a GLP-1 that causes weight loss by reducing appetite and lowering blood sugar.
Inactive ingredients in Wegovy tablets include magnesium stearate and salcaprozate sodium (SNAC). Inactive ingredients in Wegovy injections are water, salt, and other non-active ingredients that help stabilize or adjust pH. Wegovy injections are preservative-free.
Though not common, an allergic reaction to any of Wegovy’s ingredients (active or inactive) is possible. Seek medical attention for symptoms like trouble breathing, facial swelling, hives, or fainting.
Wegovy is now available in two forms: oral and injection. If you’re considering one of these options, you might be wondering, “What is in Wegovy?” The short answer is that Wegovy’s active ingredient is semaglutide, and that’s true of both forms. But a complete list of Wegovy ingredients includes inactive ingredients, too.
Below, we unpack the ingredients in Wegovy, including the differences between what’s in Wegovy oral tablets versus injections.
What is in Wegovy?
Wegovy contains one active ingredient, semaglutide. According to the drug label, Wegovy shots also contain at least three inactive ingredients, and Wegovy tablets contain two inactive ingredients.
So, what does that actually mean? Medications contain both active and inactive ingredients. The active ingredient (aka active drug) is what produces the intended effect. Everything else is an inactive ingredient, also called excipients. Examples of excipients include fillers, coatings, binders, and dyes. They do not treat your condition, but help form, stabilize, and protect the active ingredient.
Wegovy active ingredient
The active ingredient in Wegovy injections and tablets is semaglutide. (Fun fact: semaglutide is also the active ingredient in Ozempic and Rybelsus!). Semaglutide is a glucagon-like peptide-1 receptor agonist (aka GLP-1). It reduces body weight by slowing digestion, reducing your appetite, and regulating blood sugar levels.
The amount of semaglutide in each Wegovy injection pen or tablet depends on your prescribed dose. Single-dose Wegovy injection pens are filled with liquid solution that contains 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg of semaglutide. Oral Wegovy tablets contain 1.5 mg, 4 mg, 9 mg, or 25 mg of semaglutide.
Wegovy inactive ingredients
The Wegovy injection and pill contain different inactive ingredients because they are designed to deliver semaglutide to the body through different routes. The injectable version is a liquid solution that you inject under the skin, while the oral version is a powder compressed into a tablet that you swallow whole.
The Wegovy pill contains two inactive ingredients:
Salcaprozate sodium (SNAC). This inactive substance helps your body absorb the medication. SNAC protects semaglutide from being broken down by digestive enzymes in the stomach and allows it to enter the bloodstream more easily.
Magnesium stearate. This ingredient is a lubricant. It is commonly used to prevent the active ingredient from sticking to the manufacturing equipment that presses the oral tablets into shape.
Wegovy injections contain three inactive ingredients:
Disodium phosphate dihydrate. This is a type of salt used as a “buffering agent” in injection solutions. Basically, this salt helps keep the pH and chemical composition stable.
Sodium chloride. This is a tonicity agent. Tonicity describes how concentrated or diluted a solution is. Sodium chloride is used to adjust how “salty” the solution is to make it compatible with the body’s natural fluids, which is important to minimize injection site reactions.
Water for injection. Highly purified water is used to make injectable medicines. It acts as the liquid base that dissolves or carries the drug.
According to Wegovy’s drug label, an additional inactive ingredient — either hydrochloric acid or sodium hydroxide — is sometimes added to the injectable solution to adjust pH.
Does Wegovy contain preservatives?
No, Wegovy does not contain preservatives.
Preservatives are typically added to sterile medications that come in multi-dose vials or pens. Since these vials are made to be used more than once, they contain preservatives to help prevent germs from growing inside the vial. But Wegovy is not available in multi-dose vials or pens.
A Wegovy pen contains a single dose of sterile solution. It is designed to be used one time by one person, so preservatives aren’t necessary.
Can you have an allergic reaction to any Wegovy ingredients?
Yes, you can have an allergic reaction to any of Wegovy’s ingredients — just as you could to ingredients in other medications.
The good news is that serious allergic reactions to GLP-1s are rare. In clinical trials, only 2% of people taking 2.4 mg of semaglutide made antibodies against the drug. But the number of people who actually have an allergic reaction to Wegovy is probably even lower. That’s because having these antibodies makes a reaction more likely — but it doesn’t mean one will definitely happen.
So, what would an allergic reaction to Wegovy ingredients look like? Seek urgent medical attention if you experience any of these symptoms of a serious, potentially life-threatening allergic reaction from Wegovy:
Difficulty breathing or swallowing
Dizziness
Fainting
Rapid heartbeat
Facial swelling
Swelling of the tongue or throat
Hives or severe itching all over the body
Note that having an injection site reaction from the Wegovy shot, such as pain, redness, or itching, does not always mean you’re having an allergic reaction. Normally, these symptoms are typically mild and temporary. But if you have a skin reaction or rash that feels severe or spreads beyond the injection site area, it’s best to seek medical attention.
Bottom line: It’s possible to have an allergic reaction to Wegovy if you’re allergic to any one of its ingredients (active or inactive). If you have an allergy to semaglutide or any of Wegovy’s inactive ingredients, you should not take this medication.
How is Wegovy made?
Wegovy’s active ingredient, semaglutide, is made using a process called recombinant DNA technology. Here’s how it works: Scientists take pieces of DNA from different sources and combine them — kind of like a puzzle. They then put this DNA into yeast cells, which act like tiny factories to make copies of what the DNA tells them to. For Wegovy, these cells produce the peptide backbone of semaglutide — a small protein that copies what the hormone GLP-1 naturally does in your body. Semaglutide is almost identical to the real thing, matching 94% of human GLP-1.
Making Wegovy pills or injections actually usable requires recombinant DNA-produced semaglutide to be formulated with the other inactive ingredients. As of 2023, Novo Nordisk (the manufacturer of Wegovy) stated that its semaglutide was produced only at its own facilities in Denmark. The injection pens are currently manufactured in Belgium, Indiana, and North Carolina. Wegovy tablets are made in North Carolina.
Can you cut or split the Wegovy pilly?
No, you shouldn’t cut Wegovy pills. The medication instructions are clear that Wegovy pills should be swallowed whole — never split, crushed, or chewed. Splitting pills can lead to inaccurate dosing, potentially reducing benefits or increasing the risk of side effects.
Bottom line
Here’s the recap on what you need to know about the ingredients in Wegovy:
Semaglutide is the active ingredient. This key ingredient is responsible for Wegovy’s primary effects — appetite suppression and blood sugar regulation.
Inactive Wegovy ingredients differ. Wegovy injections contain water, two types of salt, and, in some cases, pH adjusters. Wegovy tablets contain SNAC (a different type of salt) to promote absorption and magnesium stearate as a flow agent.
Any ingredient (active or inactive) can cause an allergic reaction. Watch for signs of a serious reaction, such as trouble breathing, hives, or facial swelling.
Wegovy is made with recombinant DNA technology using yeast fermentation. This highly complex process enables scientists to produce semaglutide, which closely mimics GLP-1, a natural human hormone.
Consult your provider for questions about Wegovy. A healthcare professional can offer medical advice on concerns about any Wegovy ingredients, as well as whether the injection or the pill is best for you.
Frequently asked questions (FAQs)
What is the ingredient difference between Wegovy and Ozempic?
Wegovy and Ozempic contain the same active ingredient, semaglutide. They have slightly different inactive ingredients, but their primary difference is in dosage and intended purpose. Wegovy is prescribed for weight loss, and Ozempic is typically prescribed for diabetes.
What is in Wegovy that causes weight loss?
The active ingredient semaglutide in Wegovy causes weight loss. It works by reducing appetite, slowing gastric emptying, and helping regulate blood sugar.
What is SNAC in the Wegovy pill, and why is it included?
SNAC in the Wegovy pill stands for salcaprozate sodium. It’s included because it promotes absorption of oral medications that are otherwise hard to absorb or prone to breakdown by digestive enzymes.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
References
American Academy of Allergy, Asthma, and Immunology. (2024). Transient delayed onset semaglutide-associated rash. Retrieved from https://www.aaaai.org/allergist-resources/ask-the-expert/answers/2024/semaglutide
Anthony, M. S., Aroda, V. R., Parlett, L. E., et al. (2024). Risk of anaphylaxis among new users of glp-1 receptor agonists: a cohort study. Diabetes Care, 47(4), 712–719. doi:10.2337/dc23-1911. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10973896/
Aroda, V. R., Blonde, L., & Pratley, R. E. (2022). A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine & Metabolic Disorders, 23(5), 979–994. doi:10.1007/s11154-022-09735-8 Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9515042/
Chao, A. M., Tronieri, J. S., Amaro, A., et al.(2022). Clinical insight on semaglutide for chronic weight management in adults: patient selection and special considerations. Drug Design, Development and Therapy, 16, 4449–4461. doi:10.2147/DDDT.S365416. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9807016/
Chendo, C., Pinto, J. F., & Paisana, M. C. (2023). Comprehensive powder flow characterization with reduced testing. International Journal of Pharmaceutics, 642, 123107. doi:10.1016/j.ijpharm.2023.123107. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S0378517323005276
DailyMed. (2025). WEGOVY- semaglutide injection, solution; WEGOVY- semaglutide tablet. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
European Medicines Agency. (n.d.). Annex I: Summary of product characteristics. Retrieved from https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
Fick, M. (2023). How Novo Nordisk makes its weight-loss drug Wegovy. Reuters. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/how-novo-nordisk-makes-its-weight-loss-drug-wegovy-2023-11-01/
Grissinger M. (2010). Tablet splitting—only if you “half” to. Pharmacy and Therapeutics, 35(2), 69–70. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827917/
Gunawardana, C. A., Kong, A., Wanapun, D., et al. (2023). Understanding the role of magnesium stearate in lowering punch sticking propensity of drugs during compression. International Journal of Pharmaceutics, 640, 123016. doi:10.1016/j.ijpharm.2023.123016 Retrieved from https://pubmed.ncbi.nlm.nih.gov/37156307/
Jahagirdar, D. & Mahood, Q.(2023).Semaglutide for type 2 diabetes. CADTH Health Technology Review [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK598216/
Jost Chemical. (n.d.). Sodium phosphate dibasic dihydrate USP granular. Retrieved from https://www.jostchemical.com/products/sodium/productcode2775/
Kaiser, M. & McAllister, E.W. (2023). Buffering agent. Pipeline Rules of Thumb Handbook (Ninth Edition). Retrieved from https://www.sciencedirect.com/topics/engineering/buffering-agent
Kolata, G. (2023). We Know Where New Weight Loss Drugs Came From, but Not Why They Work. New York Times. Retrieved from https://www.nytimes.com/2023/08/17/health/weight-loss-drugs-obesity-ozempic-wegovy.html
Kommu, S. & Whitfield, P. (2024). Semalutide. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK603723/
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: National Institute of Diabetes and Digestive and Kidney Diseases. (2025). Semaglutide. Retrieved on January 15, 2026, from https://www.ncbi.nlm.nih.gov/books/NBK548574/
Mahar, R., Chakraborty, A., and Nainwal, N. (2022). The influence of carrier type, physical characteristics, and blending techniques on the performance of dry powder inhalers. Journal of Drug Delivery Science and Technology. Retrieved from https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/magnesium-stearate
Moore, M.H. & Eanes, Z. (2026). World's first weight loss pill is made in the Triangle. Axios Raleigh. Retrieved from https://www.axios.com/local/raleigh/2026/01/12/wegovy-weight-loss-the-triangle-north-carolina
National Center for Biotechnology Information (2026). PubChem compound summary for CID 23669833, salcaprozate sodium. Retrieved January 14, 2026 from https://pubchem.ncbi.nlm.nih.gov/compound/Salcaprozate-Sodium.
National Human Genome Research Institute. (2026). Recombinant DNA Technology. Retrieved from https://www.genome.gov/genetics-glossary/Recombinant-DNA-Technology
National Institutes of Health Dietary Supplement Label Database. (2026). Disodium phosphate dihydrate. Retrieved from https://dsld.od.nih.gov/ingredient/Disodium+Phosphate+Dihydrate
Novo Nordisk. (2025). Wegovy; semaglutide injection. U.S. Food and Drug Administration (FDA). Retrieved from https://www.novo-pi.com/wegovy.pdf
Rao, V. A., Kim, J. J., Patel, D. S., et al. (2020). A comprehensive scientific survey of excipients used in currently marketed, therapeutic biological drug products. Pharmaceutical Research, 37(10), 200. doi:10.1007/s11095-020-02919-4 Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9010397/
Shitole, S., Shinde, S., Waghmare, S., et al. (2022). A review on preservatives used in pharmaceuticals and impacts on health. Iconic Research And Engineering Journals; 5(7): 131-140. Retrieved from https://www.irejournals.com/formatedpaper/1703118.pdf
Swanson S. J. (2024). What are clinically significant anti-drug antibodies and why is it important to identify them. Frontiers; 15. doi:https://doi.org/10.3389/fimmu.2024.1401178. Retrieved from https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1401178/full
U.S. Food and Drug Administration. (2012). Sodium Chloride Injection, USP, 0.9%. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202832s001lbl.pdf
U.S. Food and Drug Administration. (2022). Inactive Ingredients in Approved Drug Products Search: Frequently Asked Questions. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-approved-drug-products-search-frequently-asked-questions
U.S. Food and Drug Administration. (2025). Highlights of Prescribing Information: WEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use.. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. doi:10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183














